Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
Role of Anti–CD38 Antibody Therapy in Induction and Maintenance in Newly Diagnosed Multiple Myeloma: How to Adopt in Clinical Practice
Tip Card: The VRd Regimen by International Myeloma Foundation - Issuu
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. - Abstract - Europe PMC
Frontline Therapy in Multiple Myeloma
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Mohamad Mohty on Twitter: "VRD lite is a key player in my opinion @Mohty_EBMT #ASH17 https://t.co/eHqUTtQwMU" / Twitter
Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis | SpringerLink
Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Current approaches to management of newly diagnosed multiple myeloma - Goel - 2022 - American Journal of Hematology - Wiley Online Library
Induction Therapy for Newly Diagnosed Multiple Myeloma
Final Thoughts on Case Study and Treating Multiple Myeloma
Comparing Drug Combinations for Newly Diagnosed Multiple Myeloma When a Stem Cell Transplant is Not a Medically Suitable Treatment | SWOG
Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes
Designing a Therapy Sequence for the Treatment of Multiple Myeloma
Managing A Case of Newly-Diagnosed Transplant-Ineligible MM
移植非適応での多発性骨髄腫に対するRVD lite(A Phase 2 Study of Modified Lenalidomide, Bortezomib and Dexamethasone in Transplant-Ineligible Multiple Myeloma ) - はくいのてんしちゃん論文編
Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients | Future Oncology
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate
Cancers | Free Full-Text | 30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Understanding the VRd Regimen for Newly Diagnosed Myeloma by International Myeloma Foundation - Issuu
Multiple Myeloma Tumor Board: Maintenance, Consolidation, and Continuous Therapy (Transcript)
(PDF) Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
